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Cancer chemotherapy should aim to benefit
patients by improving either the duration of
survival or the quality of that survival. Patient
survival is measured easily, but valid methods for
the assessment of physical, social and emotional
health have been more difficult to develop. The
definition of quality of life (QL) is essentially a
philosophical problem and there are no "gold
standards" to which QL assessments can be
compared. However the development of reliable
measures of QL is important since the aim of most
trials of chemotherapy is palliation, and the
assumption that tumour shrinkage correlates with
overall benefit to patients may not always be
justified.
A number of methods for assessing QL have
been reported, including the QL Index (Spitzer et
al., 1981): The Sickness Impact Profile (Berger et
al., 1981a, b); and linear analogue self-assessment
(LASA) (Priestman & Baum, 1976). A QL
instrument based upon LASA technique has been
developed at this institute and is the subject of a
previous report (Selby et al., 1984). This instrument
appears to be a valid measure of QL parameters,
gives reproducible results and is manageable in the
clinical setting.
In the present study we have applied the QL
instrument to two groups of patients taking part in
a randomized trial of the use of either high dose or
low dose chemotherapy for metastatic breast
cancer. We have used the instrument to address
three questions:
(i) Does the instrument allow discrimination
between two groups of patients with similar disease
parameters but whose treatment would be expected
to elicit quite different levels of toxicity?
(ii) How is patient recall of chemotheray toxicity
influenced by the timing of QL assessment in
relation to chemotherapy?
(iii) What agreement is there between patient and
physician assessment of the same aspect of QL?
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Study design The QL instrument has been
described in detail previously (Selby et al., 1984). It
consists of 31 descriptive categories (dimensions)
which assess the patient's function and behaviour,
features related to breast cancer, and treatment-
related effects (Table I). Each dimension is listed
above a 1Ocm line anchored at its ends by
descriptive phrases (Figure 1). The right hand end
describes normality or the absence of a symptom
and the left hand end the opposite extreme. The
patient was asked to mark each linear analogue
scale at a point which she felt best described her
state for the particular dimension. The instrument
can also be used by an independent observer to
make an assessment on each dimension for each
patient. Patient and observer responses are scored
by measuring the distance (in cm) from the left of
the line to the mark, giving a range of scores from
Oto 10.
no vomiting extremely severe
vomiting -
Figure 1 Example of linear analogue scale for the
dimension ofvomiting.
Twenty-five patients taking part in a prospective,
randomized trial comparing low dose CMF
(cyclophosphamide 300mgM -2, methotrexate
20mgM-2, fluorouracil 300mgM 2, all given i.v.
every 21 days) with high dose CMF
(cyclophosphamide 600mg M -2, methotrexate
40mgM -2, fluorouracil 600mgM 2 given by the
same schedule) were asked to enter this QL study.
Twelve patients received low dose CMF and 13
patients received high dose CMF. All patients had
received between 2 and 5 courses ofchemotherapy.
Patients were assessed on two occasions (Table
II). In this study the independent observer was a
physician (D.B.) who was not involved in the
clinical management of these patients. The first
asessment occurred in the clinic 3 weeks after a
course of chemotherapy, just before the
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Table I Quality of life dimensions
A. General-health related
dimensions
1. Mobility around home, town or country
2. Regular out-of-home employment
3. Self-care
4. Physical activity
5. Recreation, pastimes or hobbies
6. Anxiety
7. Social life, meeting and dealing
with people outside the family
8. Sleep (reduced or increased)
9. Depression
10. Family relationships and marriagc
11. Housework
12. Speech
13. Writing
14. Alertness and mental function
15. Anger
16. Appetite (reduced or increased)
Table II Summary of assessment procedure
First Assessment (3 weeks after chemotherapy)
1. Physician assessment by interview in clinic
2. Patient LASA
3. Then chemotherapy administration
Second Assessment (24h later)
1. Physician assessment by telephone interview
2. Patient LASA
administration of the next course. This is the usual
setting in which a physician would assess the
toxicity of a particular regimen of chemotherapy.
Patients were asked to recall how they had felt in
the 24h following the last course of chemotherapy.
The second assessment occurred the following day,
24h after another identical course of chemotherapy.
Each assessment consisted of a standard clinical
interview by the physician, who was blinded to the
doses of CMF being administered in order to
eliminate bias. Following the interview the patient
was asked to complete the QL instrument. The
physician, using a separate QL instrument, made an
assessment of each dimension for that patient,
based upon information obtained in the clinical
interview. Patient and physician assessments were
performed independently and neither had access to
the other's assessment. The second assessment, 24h
later, was of similar format except that on this
occasion the interview was conducted by telephone.
Neither physician nor patient had access to their
own previous assessment.
B. Disease related
dimensions
1.
2.
3.
4.
5.
6.
Pain
Breathing
Fatigue
Appearance of body
Attractiveness to opposite sex
Anxiety
C. Treatment related
dimensions
1. Nausea
2. Vomiting
3. Alopecia
4. Stomatitis
5. Dysuria
6. Diarrhoea
7. Constipation
Scores for most items had a unimodal
distribution that was skewed toward the end of the
scale indicating normality or absence of a symptom.
We have used non-parametric methods to analyze
our data because of this skewed distribution. The
degree of correlation between patient and physician
scores was calculated by Spearman's rank
correlation. Comparison of scores for each
dimension between patients receiving high and low
dose chemotherapy was performed using the
Wilcoxon rank sum test. Patient groups were
comparable for age, prior therapy and distribution
of metastatic disease. Thus we would not expect to
detect differences in general-health or disease
related dimensions between these two-well matched
groups. Our analysis has concentrated upon
dimensions related to toxicity of treatment.
Median scores and range of scores for patient
and physician assessment of dimensions related to
treatment toxicity are shown in Table III.
Comparison of patient scores from the high dose
group with the low dose group, at the first
assessment (3 weeks after chemotherapy), showed a
statistically significant difference for diarrhoea
(P=0.05). Differences in scores for alopecia
approach significance (P=0.08). Comparison of
physician scores at the first assessment showed
statistically significant differences for alopecia
(P=0.05) and diarrhoea (P=0.03). Thus at the first
assessment discrimination between the two groups
could be made on the basis of two out of the six
toxicity dimensions. Comparison of patient scores
obtained at the second assessment (24h after
chemotherapy), showed a statistically significantQUALITY OF LIFE MEASUREMENT 579
Table III Median scores and range for patient and physician assessments of toxicity dimensions
First assessment Second assessment
(3 weeks after chemotherapy) (24h after chemotherapy)
Low dose High dose Low dose High dose
Dimension Patient Physician Patient Physician Patient Physician Patient Physician
Nausea 9.62 7.95 9.66 8.20 8.45 8.45 7.45 6.20
(5.3-9.9) (3.0-9.9) (6.6-9.9) (0-9.4) (0.6-9.9) (3.0-9.9) (2.3-9.6) (2.6-9.9)
Vomiting 9.68 9.66 9.67 9.61 9.68 9.68 7.95 8.12
(9.5-9.9) (8.1-9.9) (0-9.9) (1.4-9.9) (5.6-9.9) (3.2-9.9) (0-9.9) (1.8-9.9)
Alopecia 9.62 9.55 9.55 7.95 9.53 9.45 5.95 7.95
(8.8-9.9) (8.3-9.9) (0.9-9.9) (3.2-9.9) (5.6-9.9) (5.7-9.9) (0-9.9) (2.3-9.9)
Stomatitis 9.68 9.68 9.68 9.68 9.67 9.72 9.68 9.68
(7.7-9.9) (8.1-9.9) (9.5-9.9) (9.5-9.9) (6.1-9.9) (9.5-9.9) (8.1-9.9) (8.8-9.9)
Dysuria 9.68 9.68 9.68 9.68 9.72 9.72 9.68 9.68
(9.5-9.9) (9.5-9.9) (9.5-9.9) (9.5-9.9) (9.5-9.9) (9.5-9.9) (3.7-9.9) (3.7-9.9)
Diarrhoea 9.68 9.68 9.62 9.66 9.72 9.72 9.59 9.59
(9.1-9.9) (9.5-9.9) (5.7-9.9) (5.4-9.9) (9.5-9.9) (9.7-9.9) (5.2-9.9) (7.4-9.9)
difference between the two groups for vomiting
(P=0.002) -and alopecia (P=0.04), while the
difference for diarrhoea approached significance
(P=0.08). When physician scores from this second
assessment were compared, statistically significant
differences were found for nausea (P=0.04),
vomiting (P=0.01) and diarrhoea (P=0.05). At this
second assessment discrimination between the high
and low dose CMF groups could be made on four
of the six toxicity dimensions.
Table IV shows Spearman's rank correlation
coefficients for patient and physician scores of
toxicity dimensions. Good agreement is seen for
most dimensions (r, >0.5). The correlation
coefficient was <0.5 for dysuria: however, patient
and physician scores were high (mean>9.0) with
small variance, so that substantial agreement is not
evident because of poor dispersal of data. There
was also good agreement for the general health and
disease related dimensions (data not shown). Only
Table IV Spearman's rank correlation
coefficient of toxicity scores from self-
assessment and assessment by a
physician
Dimension rs P
Nausea 0.65 0.0001
Vomiting 0.79 0.0001
Alopecia 0.56 0.0003
Stomatitis 0.69 0.0001
Dysuria 0.47 0.0028
Diarrhoea 0.79 0.0001
for appearance, relationships, hobbies, anxiety,
concentration, anger, breathing and sleep were
correlation coefficients less than 0.5. Once again
substantial agreement was masked by poor
dispersal of the data for concentration and
breathing. In general there appears to be good
agreement between self-rating and independent
observer assessment of the same QL dimension.
Differences in toxicity between high and low dose
CMF regimens are to be expected. Our results
demonstrate that this QL instrument can
discriminate between different levels of treatment
related toxicity, even among a small patient sample.
We found differences between the patient groups in
the first assessment made 3 weeks after
chemotherapy for the dimensions of alopecia and
diarrhoea; differences in the second assessment at
24h after chemotherapy were present for the
dimensions of nausea, vomiting, alopecia, and
diarrhoea. It seems likely that patient recall has
underestimated toxicity experienced 3 weeks
previously. The toxicities of alopecia and diarrhoea
may be more lingering and thus more easily
recalled than the more acute and short-lived
toxicities of nausea and vomiting. There appears to
be better recall of acute toxicity when QL
assessment is made closer to the time chemotherapy
administration.
Currently the evaluation of this QL instrument
shows that there are minor differences in
discriminative capacity when the instrument is used
for self-rating compared with its use by an
independent observer. Although the good
correlation between patient and physician scores580 D.R. BELL et al.
indicate that they were both assessing similar
aspects of QL, the minor discriminative differences
suggests that the most valuable QL information
may come from combining self-rating with
assessment by an independent observer. Currently
a larger study is underway at this institution: its
aims are to determine whether or not differences
may exist in other dimensions between groups of
patients with breast cancer, to assess change in
LASA with time, and to correlate change in LASA
with response to chemotherspy.
Quality of life assessment should become an
integral part of all clinical trials that seek to assess
the impact of treatment on palliation. The present
instrument has potential for routine clinical use. It
can be used readily by patients themselves as well
as by independent observers, and we have shown
evidence of its discriminative capacity in this small
group of patients. Information on QL is critical in
the determination of the overall effectiveness of
chemotherapy regimens and in the comparison of
different regimens.
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